首页 | 本学科首页   官方微博 | 高级检索  
     


The cost implications of prostate cancer screening in the Medicare population
Authors:Xiaomei Ma PhD  Rong Wang PhD  Jessica B. Long MPH  Joseph S. Ross MD  MHS  Pamela R. Soulos MPH  James B. Yu MD  Danil V. Makarov MD  MHS  Heather T. Gold PhD  Cary P. Gross MD
Affiliation:1. Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut;2. Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University, New Haven, Connecticut;3. Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut;4. Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Connecticut;5. Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut;6. Departments of Urology and Population Sciences, New York University Langone Medical Center, New York University;7. Department of Urology and Nephrology Section, New York Harbor Veterans Affairs Healthcare System, New York, New York;8. Departments of Population Health and Medicine, New York University School of Medicine and New York University Cancer Institute, New York, New York
Abstract:
Keywords:prostate cancer  prostate‐specific antigen  screening  stage  cost
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号